Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
AstraZeneca Pharma India Limited and Mankind Pharma partner to accelerate access to asthma medicine for patients in India11-03-2024
11-03-2024
Mankind Pharma Ltd - 543904 - Intimation For Receipt Of Approval For Reclassification Of Shareholding From 'Promoter & Promoter Group' Category To 'Public' Category Of Mankind Pharma Limited ('The Company') Under Regulation 31A Of The Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
With reference to the captioned subject and application made by the Company to BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on November 27, 2023 regarding reclassification of EzeRx Health Tech Private Limited from "Promoter and Promoter Group" Category to "Public" Category, we wish to inform you that the Company has received the approval from BSE and NSE for such reclassification in accordance with provisions of Regulation 31A of the Listing Regulations on March 04, 2024.05-03-2024
Mankind Pharma Ltd - 543904 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522-02-2024
Mankind Pharma Ltd - 543904 - Intimation For Sale Of Equity Shares Of The Mankind Pharma Limited By Promoter And Promoter Group Members For Achieving Minimum Public Shareholding
Intimation for sale of equity shares of the Mankind Pharma Limited by Promoter and Promoter Group members for achieving Minimum Public Shareholding09-02-2024
Three Mankind Pharma Promoters Pare 1.58% Stake For Rs 1,365.5 Crore
New World Fund bought 17.66 lakh shares, while the Government of Singapore mopped up 16.8 lakh shares.08-02-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation in (i) Axis Capital India Conference and (ii) Kotak''s Chasing Growth Conference07-02-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Investor Conference Call for Q3 FY24 - Transcript07-02-2024
Mankind Pharma Ltd - 543904 - Proposed Sale By Promoter And Promoter Group To Achieve Minimum Public Shareholding
Proposed sale by Promoter and Promoter Group to achieve Minimum Public Shareholding07-02-2024
Mankind Pharma Q3 Results Review - Robust Growth In India Coupled With Strong Exports: Nirmal Bang
We expect revenue/Ebitda/profit after tax compound annual growth rate of 16%/31.6%/37% over FY23-FY25E with margin improvement of 580 bps05-02-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Conference Call for Q3 FY24- Audio Recording02-02-2024